Servatrix Biomed S.L.

Servatrix Biomed S.L. is a biotech spin-off from the Autonomous University of Madrid (UAM), founded with the purpose of revolutioning the treatment of highly prevalent global chronic pathologies.

The company focuses its core operations on tackling Metabolic Dysfunction-Associated Steatohepatitis (MASH), a severe form of fatty liver disease that currently affects over 25% of the world's population and lacks effective therapeutic solutions on the market.

Servatrix's main scientific and competitive edge lies in its drug discovery platform centered on the NRF2 transcription factor, the master cellular regulator that protects organs against oxidative, inflammatory, and metabolic stress. Based on over 15 years of rigorous academic research led by Prof. Antonio Cuadrado, one of the world's leading experts in NRF2 molecular biology, the company has developed a proprietary, patent-protected pharmacological pipeline. Their innovative approach relies on the moderate and chronic activation of this factor at near-physiological levels, having already demonstrated remarkable protective efficacy in preclinical models.

Combining academic excellence with solid corporate experience, the management and scientific team positions Servatrix Biomed as a promising example of technology transfer in Spain, aiming for a meaningful impact on global healthcare.